Publications by authors named "Volker Wacheck"

57Publications

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Invest New Drugs 2020 12 23;38(6):1836-1845. Epub 2020 Jun 23.

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

View Article and Find Full Text PDF
December 2020

MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.

J Surg Oncol 2018 Jun 22;117(8):1679-1686. Epub 2018 May 22.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.

View Article and Find Full Text PDF
June 2018

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

PLoS One 2014 29;9(1):e84417. Epub 2014 Jan 29.

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria ; Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article and Find Full Text PDF
September 2014

Does endovenous laser ablation induce endothelial damage at the saphenofemoral junction?

Dermatol Surg 2011 Oct 26;37(10):1456-63. Epub 2011 Jul 26.

Division of General Dermatology, Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

View Article and Find Full Text PDF
October 2011

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

J Invest Dermatol 2011 Feb 4;131(2):495-503. Epub 2010 Nov 4.

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, Medical University of Vienna, Vienna, Austria.

View Article and Find Full Text PDF
February 2011

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Cancer Biol Ther 2010 Jun 18;9(11):919-27. Epub 2010 Jun 18.

Department of Clinical Pharmacology, Medical University, Vienna, Austria.

View Article and Find Full Text PDF
June 2010

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Anticancer Res 2008 Nov-Dec;28(6A):3801-8

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article and Find Full Text PDF
March 2009

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cancer Biol Ther 2008 Sep 2;7(9):1377-85. Epub 2008 Sep 2.

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.

View Article and Find Full Text PDF
September 2008

Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.

Anticancer Drugs 2007 Aug;18(7):755-61

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article and Find Full Text PDF
August 2007

[Oligonucleotide therapeutics - an emerging novel class of compounds].

Authors:
Volker Wacheck

Wien Med Wochenschr 2006 Sep;156(17-18):481-7

Abteilung für Experimentelle Onkologie/Molekulare Pharmakologie, Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Austria.

View Article and Find Full Text PDF
September 2006

Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells.

Cancer Biol Ther 2006 Oct 26;5(10):1348-54. Epub 2006 Oct 26.

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, Medical University Vienna, Vienna, Austria.

View Article and Find Full Text PDF
October 2006

Short interfering RNA (siRNA): tool or therapeutic?

Clin Sci (Lond) 2006 Jan;110(1):47-58

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
January 2006

Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

J Hepatol 2006 Jan 25;44(1):151-7. Epub 2005 Oct 25.

Section of Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article and Find Full Text PDF
January 2006

Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.

Anticancer Res 2005 Jul-Aug;25(4):2697-703

Department of Radiotherapy and Radiobiology, University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article and Find Full Text PDF
September 2005

Clusterin regulates drug-resistance in melanoma cells.

J Invest Dermatol 2005 Jun;124(6):1300-7

Department of Dermatology, Division of General Dermatology and Medical University Vienna, Vienna, Austria.

View Article and Find Full Text PDF
June 2005

Strategies for designing clinical trials for oligonucleotide therapeutics.

Authors:
Volker Wacheck

Drug Discov Today 2004 Nov;9(21):918-23

Department of Clinical Pharmacology, Section of Experimental Oncology and Molecular Pharmacology, Medical University Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
November 2004

Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells.

Cell Signal 2004 Nov;16(11):1319-27

Department of Clinical Pharmacology, Section of Experimental Oncology and Molecular Pharmacology, University of Vienna, Währinger Gürtel 18-20, A-1090, Austria.

View Article and Find Full Text PDF
November 2004

Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma.

J Invest Dermatol 2004 Sep;123(3):583-8

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
September 2004

Small interfering RNA targeting bcl-2 sensitizes malignant melanoma.

Oligonucleotides 2003 ;13(5):393-400

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Austria.

View Article and Find Full Text PDF
April 2004

A novel concept for ligand attachment to oligonucleotides via a 2'-succinyl linker.

Nucleic Acids Res 2004 2;32(2):710-8. Epub 2004 Feb 2.

Institute for Pharmaceutical Chemistry, Universität Wien, Austria.

View Article and Find Full Text PDF
April 2004

Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells.

Head Neck 2003 Sep;25(9):732-40

Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
September 2003

Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significance.

Mol Med 2002 Dec;8(12):877-84

Department of Clinical Pharmacology, Section of Experimental Oncology and Molecular Pharmacology, University Hospital Vienna, Austria.

View Article and Find Full Text PDF
December 2002

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.

Antisense Nucleic Acid Drug Dev 2002 Dec;12(6):359-67

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
December 2002

Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.

J Invest Dermatol 2003 Jan;120(1):109-15

Department of Clinical Pharmacology, Section of Experimental Oncology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article and Find Full Text PDF
January 2003

Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.

Chemotherapy 2002 Sep;48(4):189-95

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Vienna, Austria.

View Article and Find Full Text PDF
September 2002

Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy.

Int J Cancer 2002 May;99(1):29-34

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Vienna, Austria.

View Article and Find Full Text PDF
May 2002